Researchers are currently launching the CAN-TRACK trial to evaluate medical cannabis driving performance. This investigation is essential because prescriptions for therapeutic THC are increasing for patients managing chronic pain, anxiety, and insomnia. However, most road safety laws prohibit driving with any detectable THC in the system. Consequently, this study will provide critical evidence to help balance patient clinical needs with public safety regulations.

Specifically, the first phase utilizes a semi-naturalistic cohort of 72 patients. These individuals suffer from physician-diagnosed chronic pain or insomnia. Moreover, they will complete repeated on-track driving tests before and after taking their standard prescribed doses. In contrast, the second phase involves 24 healthy participants. These subjects will consume alcohol or a placebo to establish a comparative baseline for impairment levels.

Clinical Impact on Medical Cannabis Driving Performance

The primary outcome measure for the trial is lateral vehicular control, which assesses the driver's ability to maintain a steady lane position. Furthermore, clinicians will perform cognitive assessments and analyze biological samples to measure cannabinoid concentrations. Therefore, the study offers a comprehensive view of how therapeutic doses affect cognitive and motor skills. Additionally, these results will help clinicians in India and globally counsel patients more effectively regarding safe medication use.

Frequently Asked Questions

How does medical cannabis affect driving compared to alcohol?

This study benchmarks cannabis impairment against a 0.05% blood alcohol concentration. Consequently, researchers can determine if therapeutic THC doses cause impairment similar to legal alcohol limits.

Can patients with chronic pain drive safely while using THC?

The CAN-TRACK trial specifically studies patients with chronic pain to answer this question. It aims to clarify whether regular therapeutic use leads to significant impairment during real-world driving scenarios.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional physician-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

Arkell TR et al. Effects of prescribed medical cannabis and alcohol on real-world driving performance (CAN-TRACK): a study protocol for a two-phase trial. Trials. 2026 Feb 06. doi: 10.1186/s13063-026-09512-x. PMID: 41652433.

McCartney D, et al. Determining the magnitude and duration of driving impairment after cannabis use: A systematic review and meta-analysis of double-blind randomized controlled trials. Neurosci Biobehav Rev. 2021;124:189-204.

Ramaekers JG, et al. Effects of delta-9-tetrahydrocannabinol on driving performance and cognitive function. Psychopharmacology. 2020;237(12):3553-3564.